Ophthalmology Advisor’s Post

Most viewed in the last 7 days from JAMA Ophthalmology: How do outcomes differ for PDR treated with panretinal photocoagulation (PRP) first, then anti–vascular endothelial growth factor (VEGF), compared with anti-VEGF treatment first, followed by PRP? https://ja.ma/3XuJXyf

Most viewed in the last 7 days from JAMA Ophthalmology: How do outcomes differ for PDR treated with panretinal photocoagulation (PRP) first, then anti–vascular endothelial growth factor (VEGF), compared with anti-VEGF treatment first, followed by PRP? https://ja.ma/3Z9aIcM

I'm pleased to announce our latest study published in International Ophthalmology: "Canaloplasty via an ab-interno surgical technique in patients with primary angle-closure glaucoma (PACG)." Our findings highlight ab-interno canaloplasty as a safe and effective approach for #PACG—a glaucoma type traditionally not indicated for MIGS procedures. In PACG, canaloplasty achieved significant reductions in intraocular pressure (IOP) and lowered medication reliance, presenting an encouraging management option for this challenging glaucoma type. These findings may be particularly relevant for clinicians in Asia, where angle-closure glaucoma is more prevalent. For those interested in the details, I invite you to explore our research here: https://lnkd.in/db5ym4CX #GlaucomaResearch #Canaloplasty #MIGS #Ophthalmology #PACG #EyeCare #ClinicalOutcomes #glaucoma #angleclosure Springer Nature

Most viewed in the last 7 days from JAMA Ophthalmology: In-office suprachoroidal viscopexy (SCVEXY) for primary acute rhegmatogenous retinal detachment showed promising results, with 5 out of 6 patients achieving successful reattachment without additional procedures. https://ja.ma/3ZO6HJj

We need more efficacy and safety data. However, the potential of a treatment that involves no incisions, no gas/tamponade and no positioning provides an opportunity to transform care for patients with retinal detachment. For the past decade we have been trying to find ways to optimize visual function by improving the “integrity” of reattachment with less photoreceptor disruption, less retinal displacement and less outer retinal folds, all abnormalities that are more common with vitrectomy and associated with worse visual function. Scleral buckle and pneumatic retinopexy have advantages from this perspective but have their own drawbacks such as a more invasive procedure or significant positioning/compliance requirements that restrict a patient’s normal activities. Suprachoroidal Viscopexy (SCVEXY) evolved from this work. Here we have a potential treatment that may not only provide a better “integrity” of reattachment but may also offer unparalleled advantages for patient quality of life with immediate return to normal activities. Although there is much work still to be done, we are excited about what the future may hold for patients with rhegmatogenous retinal detachment and are committed to seeing it through. See article below and associated Invited Commentary in Jama Ophthalmology.

An assessment of patients with Central Retinal Artery Occlusion published in the American Journal of Ophthalmology ! - Most present within 24 hours of symptoms and with elevated inflammatory makers - Visual recovery and reperfusion are possible, both with and without the presence of a cilioretinal artery - Total and inner retinal thickening was observed on OCT at presentation, with subsequent progressive retinal thinning stabilizing after 6 months. - This modern data set can serve as a comprehensive baseline analysis for future interventional trials Great work by Sandra Hoyek and thanks to the mentorship of Demetrios Vavvas on the project! https://lnkd.in/esB_-Ub3

Hypertensive Retinopathy: ▪️Hypertensive retinopathy can be divided into the following four phases:  1. Vasoconstictive phase  2. Sclerotic phase  3. Exudative phase  4. Complications of the sclerotic phase.  ▪️While each phase may have distinct clinical feature, they often merge with each other, and the changes may not be sequential.  ▪️The vasoconstrictive and sclerotic phases are relatively asymptomatic. Loss of vision manifests most frequently with complications of the sclerotic phase, and less commonly during the exudative phase. Credit: Modern Ophthalmology.

𝐒𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐚𝐧𝐝 𝐄𝐲𝐞 𝐇𝐞𝐚𝐥𝐭𝐡: 𝐒𝐨𝐫𝐭𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐇𝐲𝐩𝐞 👁️💡 GLP-1 receptor agonists like Semaglutide are making waves—but let us not get carried away by the tide of catchy headlines! I have noticed some publications (JAMA Ophthalmology, I’m looking at you 👀) that seem also focused on clicks and attention. Sure, NAION sounds alarming, but it is still about as rare as finding a needle in a haystack. As always, we need to balance innovation with caution. For me, it’s about focusing on what truly matters—patient care—with a good dose of skepticism when the headlines start sounding too dramatic or euphoric. Find our comment: Klin Monbl Augenheilkd 2024;241(9):1021-1022. https://lnkd.in/eZ395scU How do you stay grounded amidst all the buzz? Would love to hear your thoughts! #Ophthalmology #Semaglutide #EyeHealth #ScientificBalance #InnovationAndSafety

Hypertensive Retinopathy: ▪️Hypertensive retinopathy can be divided into the following four phases:  1. Vasoconstictive phase  2. Sclerotic phase  3. Exudative phase  4. Complications of the sclerotic phase.  ▪️While each phase may have distinct clinical feature, they often merge with each other, and the changes may not be sequential.  ▪️The vasoconstrictive and sclerotic phases are relatively asymptomatic. Loss of vision manifests most frequently with complications of the sclerotic phase, and less commonly during the exudative phase. Credit: Modern Ophthalmology.

Hypertensive Retinopathy: ▪️Hypertensive retinopathy can be divided into the following four phases:  1. Vasoconstictive phase  2. Sclerotic phase  3. Exudative phase  4. Complications of the sclerotic phase.  ▪️While each phase may have distinct clinical feature, they often merge with each other, and the changes may not be sequential.  ▪️The vasoconstrictive and sclerotic phases are relatively asymptomatic. Loss of vision manifests most frequently with complications of the sclerotic phase, and less commonly during the exudative phase. Credit: Modern Ophthalmology.